World's Best Scientists 2026 revealed!
Jann N. Sarkaria

Jann N. Sarkaria

D-Index & Metrics

Medicine

D-Index
91
Citations
37728
World Ranking
11600
National Ranking
5952

Overview

Jann N. Sarkaria is a researcher affiliated with the Mayo Clinic in the United States. Their work spans multiple fields within medicine and biochemistry, genetics, and molecular biology, focusing primarily on molecular biology, genetics, oncology, radiology, nuclear medicine and imaging, as well as pulmonary and respiratory medicine.

The scientist's research addresses various topics related to cancer, particularly glioma diagnosis and treatment, DNA repair mechanisms, and cancer-related molecular pathways. Other notable areas include cancer, hypoxia, and metabolism, brain metastases and treatment, cancer research and treatments, and radiomics and machine learning in medical imaging.

Among recent publications, these papers are notable:

  • Purine metabolism regulates DNA repair and therapy resistance in glioblastoma, 2020, published in Nature Communications
  • Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance, 2021, published in Oncogene
  • Peak learning of mass spectrometry imaging data using artificial neural networks, 2021, published in Nature Communications
  • Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations, 2022, published in Journal of Clinical Oncology
  • ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL, 2020, published in Nature Communications

Frequent co-authors collaborating with this researcher include William F. Elmquist, Danielle M. Burgenske, Brett L. Carlson, Katrina K. Bakken, and Ann C. Mladek.

The researcher has a substantial presence in various scientific journals, with frequent publications in:

  • Neuro-Oncology (68 publications)
  • Cancer Research (28 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (24 publications)
  • Neuro-Oncology Advances (13 publications)
  • Molecular Cancer Therapeutics (9 publications)

Jann N. Sarkaria's work contributes to a comprehensive understanding of molecular mechanisms relevant to cancer biology and treatment, emphasizing both experimental and clinical aspects. Their research integrates molecular biology techniques, genetics, and advanced imaging and computational methods to explore therapeutic resistance, tumor plasticity, and metastatic processes.

Best Publications

  • Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

    Roel G. W. Verhaak;Katherine A. Hoadley;Elizabeth Purdom;Victoria Wang

  • The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.

    Kui Ming Chan;Dong Fang;Haiyun Gan;Rintaro Hashizume

  • Inhibition of Phosphoinositide 3-Kinase Related Kinases by the Radiosensitizing Agent Wortmannin

    Jann N. Sarkaria;Randal S. Tibbetts;Ericka C. Busby;Amy P. Kennedy

  • Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

    Anand G. Patel;Jann N. Sarkaria;Scott H. Kaufmann

  • Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

    Jann N Sarkaria;Leland S Hu;Ian F Parney;Deanna H Pafundi

  • Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake

    William A Flavahan;Qiulian Wu;Masahiro Hitomi;Nasiha Rahim

  • The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.

    Ericka C. Busby;Dru F. Leistritz;Robert T. Abraham;Larry M. Karnitz

  • Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

    Jann N. Sarkaria;Gaspar J. Kitange;C. David James;Ruth Plummer

  • THE ADVERSE EFFECT OF TREATMENT PROLONGATION IN CERVICAL CARCINOMA

    Daniel G. Petereit;Jann N. Sarkaria;Richard Chappell;John F. Fowler

  • Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

    Gaspar J. Kitange;Brett L. Carlson;Mark A. Schroeder;Patrick T. Grogan

  • Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

    Caterina Giannini;Jann N. Sarkaria;Atsushi Saito;Joon H. Uhm

  • WWP2 is an E3 ubiquitin ligase for PTEN.

    Subbareddy Maddika;Sridhar Kavela;Neelam Rani;Vivek Reddy Palicharla

  • Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

    Paul D. Brown;Sunil Krishnan;Jann N. Sarkaria;Wenting Wu

  • Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response

    Jann N. Sarkaria;Brett L. Carlson;Mark A. Schroeder;Patrick Grogan

  • Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

    Jeffrey S. Eshleman;Brett L. Carlson;Ann C. Mladek;Brian D. Kastner

  • Oral tongue cancer in young adults less than 40 years of age: rationale for aggressive therapy.

    Jann N. Sarkaria;Paul M. Harari

  • Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery.

    Brett L. Carlson;Jenny L. Pokorny;Mark A. Schroeder;Jann N. Sarkaria

  • Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma

    Rajneet K. Oberoi;Karen E. Parrish;Terence T. Sio;Rajendar K. Mittapalli

  • Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

    A. Peasland;L. Z. Wang;E. Rowling;S. Kyle

  • Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel

    Jann N. Sarkaria;Lin Yang;Patrick T. Grogan;Gaspar J. Kitange

Frequent Co-Authors

Evanthia Galanis
Evanthia Galanis Mayo Clinic
C. David James
C. David James Northwestern University
Jan C. Buckner
Jan C. Buckner Mayo Clinic
Paul D. Brown
Paul D. Brown Mayo Clinic
Marc Symons
Marc Symons Feinstein Institute for Medical Research
Brendan A.C. Harley
Brendan A.C. Harley University of Illinois at Urbana-Champaign

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative career paths in healthcare can open doors for students interested in the medical field but not pursuing a traditional MD. For instance, those interested in administrative roles may consider a health administration degree. These programs are available online and can lead to leadership positions in hospitals, clinics, and health organizations.

Allied health fields also offer accessible opportunities. If you prefer a program focused on insurance and medical records, there are online medical billing and coding schools that accept fafsa. These programs allow you to start your healthcare career quickly while potentially getting financial aid.

Pursuing nursing is another rewarding option. Some nursing schools that don't require teas or hesi exams make entry easier for aspiring nurses. Already a nurse with an ADN? You can advance your career through adn to msn bridge programs, designed for licensed nurses seeking higher degrees.

Best Scientists Citing Jann N. Sarkaria

Trending Scientists